RxDoctor Payments Data

Haritha Reddy, MD

Hematology & Oncology · Grand Rapids, MINPI 1952720906

Payments from drug & device makers

$7,131in general payments, 2019–2025

Across 124 payments — averaging $57.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$2K
  • Daiichi Sankyo Inc.$2K
  • Seagen Inc.$1K
  • Novartis$397
  • AstraZeneca$270
  • Merck$268
  • plus $1K from 27 others

What the payments were for

  • Consulting fees$4,51163%
  • Food & beverage$2,59536%
  • Education$250%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,131 in reported general payments places this provider in the 60th percentile of 282 hematology & oncology providers in Michigan.

See all hematology & oncology providers in Michigan

Medicare billing

Part B allowed, 2024
$1,740,135
Medicare patients
415
Services billed
63,838

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbrancePalbociclib82$1,253,216
KisqaliRibociclib Succinate56$978,833
VerzenioAbemaciclib26$389,288
NeulastaPegfilgrastim22$167,973
NyvepriaPegfilgrastim-Apgf23$93,345
Anastrozole708$23,461
Exemestane130$20,247
Tamoxifen Citrate149$5,650
Letrozole130$3,044
Escitalopram Oxalate67$577
Prochlorperazine Maleate49$552
Alendronate Sodium22$454
Lidocaine Hcl ViscousLidocaine Hcl13$274
Gabapentin22$263
Levothyroxine Sodium25$179

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance, Nyvepria$169$1,346,561105 claims
NovartisKisqali$397$978,83356 claims
Lilly USA, LLCVerzenio, Olanzapine$83$389,42457 claims
AmgenNeulasta$28$167,97322 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$82$17925 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 282 hematology & oncology providers in Michigan.

Other hematology & oncology in Grand Rapids

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →